Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study

Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population‐based cohort study in China

“…patients. In the Taiwan study, 15 the median follow-up time of sulphonylureas and acarbose initiators was 214 and 169 days, respectively, which was similar to our study. Third, our population was only limited to residents of Yinzhou, which is a district in Ningbo, a southeastern coastal city of China.…”

“…11 Observational studies have shown mixed results, and design issues have limited the validity of their findings. [12][13][14][15][16][17][18][19][20][21][22] For example, only six studies adopted new-user designs, 14,15,17,19,21 and among them, one study did not exclude patients that used the comparator drugs at baseline. 19 Some studies compared patients initiating sulphonylureas as combination therapy with patients initiating other oral anti-diabetic drugs (OADs) in combination without adequate control for concurrent OADs.…”

“…19 Some studies compared patients initiating sulphonylureas as combination therapy with patients initiating other oral anti-diabetic drugs (OADs) in combination without adequate control for concurrent OADs. 15,16 Moreover, most of these studies assessed the heart failure risk of sulphonylureas by comparing with metformin and an increased risk has been implied. 14,[19][20][21] ; however, such comparison induce confounding by disease severity thus metformin is not an appropriate comparator.…”

Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease

“…Moreover, recent studies reported associations of certain antidiabetes drugs with increased risk of HF. Available data suggest that thiazolidinediones may precipitate HF . A recent Taiwanese study reported that, as compared with acarbose, glinides may be associated with a higher risk of HF for people with type 2 diabetese .…”

“…Available data suggest that thiazolidinediones may precipitate HF. 38 A recent Taiwanese study reported that, as compared with acarbose, glinides may be associated with a higher risk of HF for people with type 2 diabetese. 39 Such findings are generally consistent with the present data.…”